Al Razi profit drops 66% to SAR 686,000 in 2023

Al Razi profit drops 66% to SAR 686,000 in 2023

30/03/2024 Argaam Exclusive

View other reports

Al Razi Medical Co. reported a 66% fall in 2023 net profit to SAR 686,000, from SAR 2 million a year earlier.



Financials (M)

Item 2022 2023 Change‬
Revenues 52.39 61.33 17.1 %
Gross Income 16.10 17.58 9.2 %
Operating Income 2.59 1.41 (45.4 %)
Net Income 2.01 0.69 (65.9 %)
Average Shares 1.52 1.52 -
EPS (Riyals) 1.33 0.45 (65.9 %)

The profit decline was due to the company's investment in promotions to support sales of non-pharmaceutical products on the website and branches, as well as the higher selling and distribution expenses of new branches that are in the process of growing to achieve the sales target.

 

However, revenues rose by 17.1% year-on-year (YoY), or SAR 8.9 million, driven by the increase in sales from pharmacy branches opened in late 2022 and 2023.



Total shareholders’ equity, no minority interest, reached SAR 22.4 million as of Dec. 31, 2023, from SAR 23.6 million a year earlier.

 

Historical Data

Period

Revenues (SAR mln)

Net Profit (SAR mln)

EPS (SAR)

H1 2022

24.07

0.58

0.38

H2 2022

28.32

1.43

0.94

H1 2023

30.54

0.61

0.40

H2 2023

30.79

0.08

0.05

 

View more financial results

 


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2014 - - - - - - -
Q2 2014 - - - - - - -
Q3 2014 - - - - - - -
Q4 2014 - - - - - - -
Q1 2015 - - - - - - -
Q2 2015 - - - - - - -
Q3 2015 - - - - - - -
Q4 2015 - - - - - - -
Q1 2016 - - - - - - -
Q2 2016 - - - - - - -
Q3 2016 - - - - - - -
Q4 2016 - - - - - - -
Q1 2017 - - - - - - -
Q2 2017 - - - - - - -
Q3 2017 - - - - - - -
Q4 2017 - - - - - - -
Q1 2018 - - - - - - -
Q2 2018 - - - - - - -
Q3 2018 - - - - - - -
Q4 2018 - - - - - - -
Q1 2019 - - - - - - -
Q2 2019 - - - - - - -
Q3 2019 - - - - - - -
Q4 2019 - - - - - - -
Q1 2020 - - - - - - -
Q2 2020 - - - - - - -
Q3 2020 - - - - - - -
Q4 2020 - - - - - - -
Q1 2021 - - - - - - -
Q2 2021 - - - - - - -
Q3 2021 - - - - - - -
Q4 2021 - - - - - - -
Q1 2022 - - - - - - -
Q2 2022 - - - - - - -
Q3 2022 - - - - - - -
Q4 2022 - - - - - - -
Q1 2023 - - - - - - -
Q2 2023 - - - - - - -
Q3 2023 - - - - - - -
Q4 2023 - - - - - - -
2023 61.33 17.1 % 17.58 9.2 % 0.69 (65.9 %) 0.45

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 - - -
2023 28.67 % 8.32 % 1.12 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2014 - - - -
Q2 2014 - - - -
Q3 2014 - - - -
Q4 2014 - - - -
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 - - - -
Q2 2021 - - - -
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 - - - -
Q2 2022 - - - -
Q3 2022 - - - -
Q4 2022 - - - -
Q1 2023 - - - -
Q2 2023 - - - -
Q3 2023 - - - -
Q4 2023 - - - -

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 - - -

Business Segments (Million)

Compared With The
Period Medicines Cosmetics Baby milk Medical equipment Medical preparations Other


Financial Ratios
Current
Market Cap (M Riyal) 73.11
Enterprise Value (EV) (M) 75.12
Shares Outstanding ((M)) 1.52
Book Value (BV) ( Riyal) 14.72
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) More than 100
Price/book 3.27
more

Share Price

Al-Razi Medical Co.
48.10
(1.90) (3.80 %)

Al-Razi Medical Co. (ALRAZI)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.